These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35995138)

  • 1. A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice.
    Bahreyni A; Liu H; Mohamud Y; Xue YC; Zhang J; Luo H
    Cancer Lett; 2022 Nov; 548():215849. PubMed ID: 35995138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced genomic stability of new miRNA-regulated oncolytic coxsackievirus B3.
    Liu H; Bahreyni A; Mohamud Y; Xue YC; Jia WWG; Luo H
    Mol Ther Oncolytics; 2022 Dec; 27():89-99. PubMed ID: 36321136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3.
    Sagara M; Miyamoto S; Itoh S; Soda Y; Tani K
    Anticancer Res; 2021 Jan; 41(1):81-89. PubMed ID: 33419801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer.
    Liu H; Xue YC; Deng H; Mohamud Y; Ng CS; Chu A; Lim CJ; Lockwood WW; Jia WWG; Luo H
    Mol Ther Oncolytics; 2020 Mar; 16():207-218. PubMed ID: 32123721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extremely Low Organ Toxicity and Strong Antitumor Activity of miR-34-Regulated Oncolytic Coxsackievirus B3.
    Jia Y; Miyamoto S; Soda Y; Takishima Y; Sagara M; Liao J; Hirose L; Hijikata Y; Miura Y; Hara K; Iwanaga A; Ota Y; Tani K
    Mol Ther Oncolytics; 2019 Mar; 12():246-258. PubMed ID: 30891489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coxsackievirus B3 engineered to contain microRNA targets for muscle-specific microRNAs displays attenuated cardiotropic virulence in mice.
    He F; Yao H; Wang J; Xiao Z; Xin L; Liu Z; Ma X; Sun J; Jin Q; Liu Z
    J Virol; 2015 Jan; 89(2):908-16. PubMed ID: 25339771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered coxsackievirus B3 containing multiple organ-specific miRNA targets showed attenuated viral tropism and protective immunity.
    Xiao Z; He F; Feng M; Liu Z; Liu Z; Li S; Wang W; Yao H; Wu J
    Infect Genet Evol; 2022 Sep; 103():105316. PubMed ID: 35718333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-342-5p suppresses coxsackievirus B3 biosynthesis by targeting the 2C-coding region.
    Wang L; Qin Y; Tong L; Wu S; Wang Q; Jiao Q; Guo Z; Lin L; Wang R; Zhao W; Zhong Z
    Antiviral Res; 2012 Feb; 93(2):270-279. PubMed ID: 22197249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma.
    Miyamoto S; Inoue H; Nakamura T; Yamada M; Sakamoto C; Urata Y; Okazaki T; Marumoto T; Takahashi A; Takayama K; Nakanishi Y; Shimizu H; Tani K
    Cancer Res; 2012 May; 72(10):2609-21. PubMed ID: 22461509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-375-mediated suppression of engineered coxsackievirus B3 in pancreatic cells.
    Pryshliak M; Hazini A; Knoch K; Dieringer B; Tolksdorf B; Solimena M; Kurreck J; Pinkert S; Fechner H
    FEBS Lett; 2020 Feb; 594(4):763-775. PubMed ID: 31643074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas.
    Pinkert S; Pryshliak M; Pappritz K; Knoch K; Hazini A; Dieringer B; Schaar K; Dong F; Hinze L; Lin J; Lassner D; Klopfleisch R; Solimena M; Tschöpe C; Kaya Z; El-Shafeey M; Beling A; Kurreck J; Van Linthout S; Klingel K; Fechner H
    Cardiovasc Res; 2020 Aug; 116(10):1756-1766. PubMed ID: 31598635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of a microRNA-Regulated Oncolytic Coxsackievirus B3.
    Dieringer B; Elsner L; Hazini A; Kurreck J; Fechner H
    Methods Mol Biol; 2022; 2521():259-282. PubMed ID: 35733003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma.
    Hazini A; Pryshliak M; Brückner V; Klingel K; Sauter M; Pinkert S; Kurreck J; Fechner H
    Hum Gene Ther; 2018 Nov; 29(11):1301-1314. PubMed ID: 29739251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coxsackievirus B3-Its Potential as an Oncolytic Virus.
    Geisler A; Hazini A; Heimann L; Kurreck J; Fechner H
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33919076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oncolytic coxsackievirus therapy as an immunostimulator].
    Miyamoto S; Sagara M; Kohara H; Tani K
    Rinsho Ketsueki; 2017; 58(8):977-982. PubMed ID: 28883283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The suppressive effect of MiR-490 on coxsackievirus B3 replication].
    Wang LL; Zhong ZH; Wang Q; Lu P; Li M; Xu HY
    Bing Du Xue Bao; 2014 Nov; 30(6):619-23. PubMed ID: 25868275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel recombinant coxsackievirus B3 with genetically inserted basic peptide elicits robust antitumor activity against lung cancer.
    Cai L; Liu Z
    Cancer Med; 2020 Jul; 9(14):5210-5220. PubMed ID: 32459400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temperature-sensitive mutant of coxsackievirus B3 establishes resistance in neonatal mice that protects them during adolescence against coxsackievirus B3-induced myocarditis.
    Gauntt CJ; Paque RE; Trousdale MD; Gudvangen RJ; Barr DT; Lipotich GJ; Nealon TJ; Duffey PS
    Infect Immun; 1983 Feb; 39(2):851-64. PubMed ID: 6299950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-375- and miR-1-Regulated Coxsackievirus B3 Has No Pancreas and Heart Toxicity But Strong Antitumor Efficiency in Colorectal Carcinomas.
    Hazini A; Dieringer B; Pryshliak M; Knoch KP; Heimann L; Tolksdorf B; Pappritz K; El-Shafeey M; Solimena M; Beling A; Kurreck J; Klingel K; Fechner H
    Hum Gene Ther; 2021 Feb; 32(3-4):216-230. PubMed ID: 33481658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-203 enhances coxsackievirus B3 replication through targeting zinc finger protein-148.
    Hemida MG; Ye X; Zhang HM; Hanson PJ; Liu Z; McManus BM; Yang D
    Cell Mol Life Sci; 2013 Jan; 70(2):277-91. PubMed ID: 22842794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.